{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:42:10Z","timestamp":1758631330405,"version":"3.43.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","award":["JPMJPF2017"],"award-info":[{"award-number":["JPMJPF2017"]}],"id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijrobp.2024.12.019","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T12:12:39Z","timestamp":1735819959000},"page":"168-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined Molecular Subclass and Immune Phenotype Correlate to Atezolizumab Plus Radiation Therapy Response in Invasive Bladder Cancer: BPT-ART Phase 2 Study"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-4791","authenticated-orcid":false,"given":"Yoshiyuki","family":"Nagumo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masae","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan J.","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.12.019_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0002","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN guidelines\u00ae insights: Bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100724","article-title":"Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) \u2013 A study protocol for an open-label, phase II, multicenter study","volume":"21","author":"Sekino","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0004","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0005","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0006","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0007","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0008","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: Interim analysis from a multicenter, open-label, prospective phase 2 trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0009","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node\u2013negative invasive bladder cancer: Single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0011","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: A phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","article-title":"Urothelial carcinoma: Variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes","volume":"53","author":"Takahara","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0014","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/iju.14885","article-title":"Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors","volume":"29","author":"Kawahara","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, Snpeff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0018","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.eururo.2017.12.001","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes","volume":"73","author":"Galsky","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0019","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1158\/1078-0432.CCR-23-0792","article-title":"Genomic tumor correlates of clinical outcomes following organ-sparing chemoradiation therapy for bladder cancer","volume":"29","author":"Kamran","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0020","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euo.2023.05.013","article-title":"Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. Final results of NRG oncology RTOG 0524-a phase 1\/2 trial of paclitaxel + trastuzumab with daily radiation or paclitaxel alone with daily irradiation","volume":"7","author":"Dahl","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-a randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0023","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2024.03.015","article-title":"Prognostic significance of immune cell infiltration in muscle-invasive bladder cancer treated with definitive chemoradiation: A secondary analysis of RTOG 0524 and RTOG 0712","volume":"7","author":"Rana","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2019.01.011","article-title":"Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euf.2022.12.012","article-title":"Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: The MK-3475-992\/KEYNOTE-992 trial","volume":"9","author":"Tissot","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0026","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s10147-023-02386-y","article-title":"Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: Yodo study","volume":"28","author":"Nishiyama","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0027","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0028","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the abacus trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0029","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0030","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0031","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: The phase 1B NABUCCO trial","volume":"29","author":"van Dorp","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0032","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lungcan.2021.01.013","article-title":"Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study","volume":"153","author":"Hashemi","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0034","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1096\/fj.201700740R","article-title":"Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy","volume":"32","author":"Wang","year":"2018","journal-title":"FASEB J"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0036","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.neo.2016.08.002","article-title":"CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer","volume":"18","author":"Miyake","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0037","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-023-03949-3","article-title":"Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis","volume":"21","author":"Koll","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0038","doi-asserted-by":"crossref","first-page":"12682","DOI":"10.1038\/s41598-017-12892-5","article-title":"Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer","volume":"7","author":"Tervahartiala","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0039","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12935-021-01896-x","article-title":"The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer","volume":"21","author":"Du","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","article-title":"The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer","volume":"34","author":"Horn","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0041","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The ratio of CD8 to treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0042","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic alterations in the molecular subtypes of bladder cancer: Illustration in the cancer genome atlas dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0043","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0044","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0045","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0046","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: The NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2024.12.019_bib0047","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162403774X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162403774X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:36:53Z","timestamp":1754480213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162403774X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S036030162403774X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.019","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Molecular Subclass and Immune Phenotype Correlate to Atezolizumab Plus Radiation Therapy Response in Invasive Bladder Cancer: BPT-ART Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}